Home Featured Page 3

Featured

Latest

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Psychedelic Policy Briefing: Week of July 20th, 2026

JOURNEYS: A Film Experience & Live Conversation with the Filmmakers

What Is Metaprogramming? A Practitioner’s Introduction

Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout...

Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley...

Psychedelic Policy Briefing: Week of July 13th, 2026

Backed by $11M NIDA Grant, Harvard Moves Forward on Ibogaine for...

Keeping Up with the Feds: From FDA to HRSA, Washington Backs...

The Rush for Iboga Looks Different from Gabon

FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future...

EDITOR PICKS

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Psychedelic Policy Briefing: Week of July 20th, 2026

JOURNEYS: A Film Experience & Live Conversation with the Filmmakers

What Is Metaprogramming? A Practitioner’s Introduction

Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout...

Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley...

Psychedelic Policy Briefing: Week of July 13th, 2026

Backed by $11M NIDA Grant, Harvard Moves Forward on Ibogaine for...

Keeping Up with the Feds: From FDA to HRSA, Washington Backs...

The Rush for Iboga Looks Different from Gabon

FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future...

EDITOR PICKS

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY